Bank Julius Baer & Co’s Royalty Pharma RPRX Stock Holding History

Bank Julius Baer & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,034	Closed	-$41K	–	762
2021 Q4	$41K	Hold	1,034	–	–	﹤0.01%	672
2021 Q3	$37K	Buy	1,034 +9	+0.9%	+$350	﹤0.01%	705
2021 Q2	$42K	Buy	1,025 +650	+173%	+$27.6K	﹤0.01%	696
2021 Q1	$16K	Sell	375 -25	-6%	-$1.19K	﹤0.01%	762
2020 Q4	$20K	Buy	400 +10	+3%	+$424	﹤0.01%	746
2020 Q3	$16K	Buy	+390	New	+$16.7K	﹤0.01%	673

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank Julius Baer & Co's RPRX Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 1,034 shares — an estimated $41K sold.

Bank Julius Baer & Co first reported a position in RPRX in Q3 2020 and held it in 6 quarters. The position peaked at $42K in Q2 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Bank Julius Baer & Co reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 1,034 Royalty Pharma shares in Q1 2022, an estimated $41K.
Bank Julius Baer & Co first reported a position in Royalty Pharma in Q3 2020 and held it in 6 quarters.
Bank Julius Baer & Co's Royalty Pharma position peaked at $42K in Q2 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.